Cargando…

Cardioprotective Effect of Dexrazoxane in Patients with HER2-Positive Breast Cancer Who Receive Anthracycline Based Adjuvant Chemotherapy Followed by Trastuzumab

PURPOSE: We intended to determine whether dexrazoxane (DZR) is cardioprotective during administration of adjuvant anthracycline-based chemotherapy followed by a 1-year trastuzumab treatment. METHODS: The medical records of 228 patients who underwent surgical resection and received adjuvant chemother...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, In-Ho, Lee, Ji Eun, Youn, Ho-Joong, Song, Byung Joo, Chae, Byung Joo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Breast Cancer Society 2017
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5378583/ https://www.ncbi.nlm.nih.gov/pubmed/28382098 http://dx.doi.org/10.4048/jbc.2017.20.1.82

Ejemplares similares

The Predictive Value of Serum HER2/neu for Response to Anthracycline-Based and Trastuzumab-Based Neoadjuvant Chemotherapy
por: Lee, Jung Sun, et al.
Publicado: (2012)

Anthracycline extravasation injuries: management with dexrazoxane
por: Jordan, Karin, et al.
Publicado: (2009)

Dexrazoxane for Preventing Anthracycline Cardiotoxicity in Children with Solid Tumors
por: Choi, Hyoung Soo, et al.
Publicado: (2010)

Efficacy of Dexrazoxane in Preventing Anthracycline Cardiotoxicity in Breast Cancer
por: Macedo, Ariane V.S., et al.
Publicado: (2019)

Cardiac Protective Effects of Dexrazoxane on Animal Cardiotoxicity Model Induced by Anthracycline Combined With Trastuzumab Is Associated With Upregulation of Calpain-2
por: Zhang, Sheng, et al.
Publicado: (2015)

Dexrazoxane for cardioprotection in older adults with acute myeloid leukemia
por: Vachhani, Pankit, et al.
Publicado: (2017)

Efficacy of Dexrazoxane in Cardiac Protection in Pediatric Patients Treated With Anthracyclines
por: Rahimi, Parya, et al.
Publicado: (2023)

Concurrent administration of trastuzumab and anthracyclines as adjuvant regimen for HER2-positive breast cancer: a randomised controlled trial
por: Shen, Songjie, et al.
Publicado: (2017)

Dexrazoxane for the treatment of chemotherapy-related side effects
por: Langer, Seppo W
Publicado: (2014)

The Lack of Synergy between Carvedilol and the Preventive Effect of Dexrazoxane in the Model of Chronic Anthracycline-Induced Cardiomyopathy
por: Szponar, Jaroslaw, et al.
Publicado: (2023)

The Impact of Adding Taxanes to Anthracyclines on Women with Breast Cancer Receiving Adjuvant Chemotherapy
por: Hilaj, Erina, et al.
Publicado: (2020)

The comparison of anthracycline-based and non-anthracycline-based regimens in adjuvant chemotherapy of HER2-positive non-metastatic breast cancers
por: Najafi, Safa, et al.
Publicado: (2018)

Efficacy and safety of Dexrazoxane (DRZ) in sarcoma patients receiving high cumulative doses of anthracycline therapy – a retrospective study including 32 patients
por: Schuler, Markus K., et al.
Publicado: (2016)

Termination of trastuzumab in HER2-positive metastatic breast cancer patients who received trastuzumab beyond progression
por: Dogan, Izzet, et al.
Publicado: (2023)

Upfront dexrazoxane for the reduction of anthracycline-induced cardiotoxicity in adults with preexisting cardiomyopathy and cancer: a consecutive case series
por: Ganatra, Sarju, et al.
Publicado: (2019)

Risk Profiling of Cancer Treatment-Related Cardiovascular Disorders in Breast Cancer Patients Who Received Adjuvant Chemotherapy With Trastuzumab
por: Shinano, Hiromi, et al.
Publicado: (2020)

HER2 expression and efficacy of dose-dense anthracycline-containing adjuvant chemotherapy in breast cancer patients
por: Del Mastro, L, et al.
Publicado: (2005)

Baseline cardiac function checkup in patients with gastric or breast cancer receiving trastuzumab or anthracyclines
por: Ishii, Taisuke, et al.
Publicado: (2022)

Dexrazoxane-afforded protection against chronic anthracycline cardiotoxicity in vivo: effective rescue of cardiomyocytes from apoptotic cell death
por: Popelová, O, et al.
Publicado: (2009)

Evaluation of the cost-effectiveness of dexrazoxane for the prevention of anthracycline-related cardiotoxicity in children with sarcoma and haematologic malignancies: a European perspective
por: Dewilde, Sarah, et al.
Publicado: (2020)

Impact of dose-dense neoadjuvant chemotherapy on pathologic response and survival for HER2-positive breast cancer patients who receive trastuzumab
por: Wang, Lize, et al.
Publicado: (2021)

Phase II study of capecitabine and trastuzumab combination chemotherapy in patients with HER2 overexpressing metastatic breast cancers resistant to both anthracyclines and taxanes
por: Ishida, Takanori, et al.
Publicado: (2008)

Additional effect of anthracycline in preoperative chemotherapy with a sequential anthracycline‑containing regimen preceded by pertuzumab, trastuzumab and docetaxel combination therapy
por: Shima, Hiroaki, et al.
Publicado: (2022)

BSE and BCOS Guideline for Transthoracic Echocardiographic Assessment of Adult Cancer Patients Receiving Anthracyclines and/or Trastuzumab
por: Dobson, Rebecca, et al.
Publicado: (2021)

The cardioprotective effect of dexrazoxane (Cardioxane) is consistent with sequestration of poly(ADP-ribose) by self-assembly and not depletion of topoisomerase 2B
por: McCormack, Keith
Publicado: (2018)

Pathophysiology and preventive strategies of anthracycline-induced cardiotoxicity
por: Chung, Woo-Baek, et al.
Publicado: (2016)

Hepatitis B Reactivation During Adjuvant Anthracycline-Based Chemotherapy in Patients with Breast Cancer: A Single Institution's Experience
por: Kim, Min Kyoung, et al.
Publicado: (2007)

Cardioprotective effect of Platycodon grandiflorum in patients with early breast cancer receiving anthracycline-based chemotherapy: study protocol for a randomized controlled trial
por: Hao, Wei, et al.
Publicado: (2017)

Dual HER2 blockade with lapatinib and trastuzumab in combination with chemotherapy in metastatic gastroesophageal adenocarcinoma
por: Cheong, E. Von, et al.
Publicado: (2021)

Chemotherapy Response Assay Test and Prognosis for Breast Cancer Patients Who Have Undergone Anthracycline- and Taxane-Based Chemotherapy
por: Lee, Anbok, et al.
Publicado: (2011)

Survival Outcomes of Retreatment with Trastuzumab and Cytotoxic Chemotherapy for HER2-Positive Recurrent Patients With Breast Cancer Who Had Been Treated with Neo/adjuvant Trastuzumab Plus Multidrug Chemotherapy: A Japanese Multicenter Observational Study
por: Yamashiro, Hiroyasu, et al.
Publicado: (2018)

PB1714: DEXRAZOXANE IN HAEMATOLOGICAL PATIENTS: A META-ANALYSIS OF THE CARDIOPROTECTIVE EFFICACY, RISK OF SECONDARY MALIGNANCIES AND IMPACT IN SURVIVAL OUTCOMES
por: Pimenta, Mario Sousa, et al.
Publicado: (2023)

Impact of baseline telomere length on survival and chemotherapy related toxicity in breast cancer patients receiving (neo)adjuvant anthracycline containing chemotherapy
por: Hatse, Sigrid, et al.
Publicado: (2022)

Benefit of postoperative regional nodal irradiation in patients receiving preoperative systemic therapy with docetaxel/carboplatin/trastuzumab/pertuzumab for HER2-positive breast cancer
por: Kim, Nalee, et al.
Publicado: (2023)

Adjuvant trastuzumab and vinorelbine for early-stage HER2+ breast cancer
por: McLaughlin, Shannon, et al.
Publicado: (2023)

Scavenging Effects of Dexrazoxane on Free Radicals
por: Junjing, Zhang, et al.
Publicado: (2010)

A Retrospective Analysis for Patients with HER2-Positive Gastric Cancer Who Were Treated with Trastuzumab-Based Chemotherapy: In the Perspectives of Ethnicity and Histology
por: Yi, Jun Ho, et al.
Publicado: (2016)

Efficacy and cardiac safety of the concurrent use of trastuzumab and anthracycline-based neoadjuvant chemotherapy for HER2-positive breast cancer: a systematic review and meta-analysis
por: Wu, Yu-Tuan, et al.
Publicado: (2018)

BERENICE Final Analysis: Cardiac Safety Study of Neoadjuvant Pertuzumab, Trastuzumab, and Chemotherapy Followed by Adjuvant Pertuzumab and Trastuzumab in HER2-Positive Early Breast Cancer
por: Dang, Chau, et al.
Publicado: (2022)

Phase II Study of Vinorelbine Plus Trastuzumab in HER2 Overexpressing Metastatic Breast Cancer Pretreated with Anthracyclines and Taxanes
por: Lee, Yu Rim, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_apicu2642tblht2ueh737ni1bm